DALLAS, Aug. 4, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring biopharmaceutical company ViroPharma Inc. (Nasdaq:VPHM). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The investment report on ViroPharma Inc. (Nasdaq:VPHM) should be of particular interest to other biopharmaceutical companies: Cubist Pharmaceuticals (Nasdaq:CBST), Salix Pharmaceuticals Ltd. (Nasdaq:SLXP), AstraZeneca plc (NYSE:AZN) and GlaxoSmithKline plc (NYSE:GSK).
It is available at: http://www.stockpreacher.com/n/VPHM
ViroPharma Inc. (VPHM), a biopharmaceutical company, engages in the development and commercialization of products that address serious diseases with a focus on products used by physician specialists or in hospital settings in the United States and internationally. Its products include Vancocin HCl capsules for the treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains; and Cinryze for the prevention of hereditary angioedema attacks.
In the report, the analyst notes:
"The Company's net sales were $81.9 million for the three months ended June 30, 2009, as compared to $65.4 million for the comparative three-month period of 2008. During the second quarter, net sales of Cinryze were $25.6 million, up from $6.7 million in the first quarter.
"VPHM has two marketed products: Cinryze and Vancocin. Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product that has been approved by FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. C1 inhibitor therapy has been used acutely for more than 35 years in Europe to treat patients with C1 inhibitor deficiency. Vancocin is the only drug approved by the FDA for the treatment of antibiotic-associated pseudomembranous colitis caused by C. difficile. In addition, the Company currently has other three development programs."
To read the entire report visit: http://www.stockpreacher.com/n/VPHM
See what investors are saying about all these stocks at: http://www.stockhideout.com/
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.